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ABSTRACT
Background
Meta-analyses of antidepressant medications have reported only modest benefits over
placebo treatment, and when unpublished trial data are included, the benefit falls below
accepted criteria for clinical significance. Yet, the efficacy of the antidepressants may also
depend on the severity of initial depression scores. The purpose of this analysis is to establish
the relation of baseline severity and antidepressant efficacy using a relevant dataset of
published and unpublished clinical trials.
Methods and Findings
We obtained data on all clinical trials submitted to the US Food and Drug Administration
(FDA) for the licensing of the four new-generation antidepressants for which full datasets were
available. We then used meta-analytic techniques to assess linear and quadratic effects of initial
severity on improvement scores for drug and placebo groups and on drug–placebo difference
scores. Drug–placebo differences increased as a function of initial severity, rising from virtually
no difference at moderate levels of initial depression to a relatively small difference for patients
with very severe depression, reaching conventional criteria for clinical significance only for
patients at the upper end of the very severely depressed category. Meta-regression analyses
indicated that the relation of baseline severity and improvement was curvilinear in drug groups
and showed a strong, negative linear component in placebo groups.
Conclusions
Drug–placebo differences in antidepressant efficacy increase as a function of baseline
severity, but are relatively small even for severely depressed patients. The relationship between
initial severity and antidepressant efficacy is attributable to decreased responsiveness to
placebo among very severely depressed patients, rather than to increased responsiveness to
medication.
The Editors’ Summary of this article follows the references.
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Meta-analyses of antidepressant efﬁcacy based on data
from published trials reveal beneﬁts that are statistically
signiﬁcant, but of marginal clinical signiﬁcance [1]. Analyses
of datasets including unpublished as well as published clinical
trials reveal smaller effects that fall well below recommended
criteria for clinical effectiveness. Speciﬁcally, a meta-analysis
of clinical trial data submitted to the US Food and Drug
Administration (FDA) revealed a mean drug–placebo differ-
ence in improvement scores of 1.80 points on the Hamilton
Rating Scale of Depression (HRSD) [2], whereas the National
Institute for Clinical Excellence (NICE) used a drug–placebo
difference of three points as a criterion for clinical
signiﬁcance when establishing guidelines for the treatment
of depression in the United Kingdom [1]. Mean improvement
scores can obscure differences in improvement within
subsets of patients. Speciﬁcally, antidepressants may be
effective for severely depressed patients, but not for
moderately depressed patients [1,3,4]. The purpose of the
present analysis is to test that hypothesis (see Text S1 for the
QUOROM checklist).
Conventional meta-analyses are often limited to published
data. In the case of antidepressant medication, this limitation
has been found to result in considerable reporting bias
characterized by multiple publication, selective publication,
and selective reporting in studies sponsored by pharmaceut-
ical companies [5]. To avoid publication bias, we evaluated a
dataset that includes the complete data from all trials of the
medications, whether or not they were published. Speciﬁcally,
we analyzed the data submitted to the FDA for the licensing
of four new-generation antidepressants for which full data,
published and unpublished, were available. As part of the
licensing process, the FDA requires drug companies to report
‘‘all controlled studies related to each proposed indication’’
([6] emphasis in original). Thus, there should be no reporting
bias in the dataset we analyze.
Methods
Study Retrieval
Following the Freedom of Information Act (FOIA) [7], we
requested from the FDA all publicly releasable information
about the clinical trials for efﬁcacy conducted for marketing
approval of ﬂuoxetine, venlafaxine, nefazodone, paroxetine,
sertraline, and citalopram, the six most widely prescribed
antidepressants approved between 1987 and 1999 [2], which
represent all but one of the selective serotonin reuptake
inhibitors (SSRIs) approved during the study period. In reply,
the agency provided photocopies of the medical and
statistical reviews of the sponsors’ New Drug Applications.
The FDA requires that information on all industry-sponsored
trials be submitted as part of the approval process; hence the
ﬁles sent to us by the FDA should contain information on all
trials conducted prior to the approval of each medication.
This strategy omits trials conducted after approval was
granted.
Although sponsors are required to submit information on
all trials, the FDA public disclosure did not include mean
changes for nine trials that were deemed adequate and well
controlled but that failed to achieve a statistically signiﬁcant
beneﬁt for drug over placebo. Data for four of these trials
were available from a pharmaceutical company Web site in
January 2007 and were obtained from the GlaxoSmithKline
clinical trial register (http://ctr.gsk.co.uk/Summary/paroxetine/
studylist.asp).
We also identiﬁed published versions of the FDA trials via a
PubMed literature search (from January 1985 through May
2007) using the keywords depression; depressive; depressed; and
placebo; speciﬁc names of antidepressant medications; and
names of investigators from the FDA trials. Potentially
relevant studies were also identiﬁed through references of
retrieved and review articles and from a partially overlapping
list of published versions of trials submitted to the Swedish
drug regulatory authority [5]. Using a standardized protocol,
all retrieved abstracts and publications were compared to the
FDA trials. The match between each published study and its
corresponding FDA trial was independently established with
100% agreement by two investigators (BJD and a research
assistant).
Selection
Forty-seven clinical trials were identiﬁed in the data
obtained from the FDA. The trial ﬂow is illustrated in Figure
1. Inclusion of a drug type for which unsuccessful trials were
excluded biases overall results in favor of that drug type, in a
way that is akin to publication bias. The purpose in using the
FDA dataset is precisely to avoid this type of bias by including
all trials of each medication assessed. Therefore, we present
analyses only for those medications for which mean change
scores on all trials were available.
Validity Assessment
The FDA requires that rigorous standards be followed for
the conduct of all efﬁcacy trials for marketing approval [8]
and also sets speciﬁc agency standards for clinical trials of
antidepressant drugs [9]. In addition, the FDA independently
reviews the clinical trial methods, statistical procedures, and
results. The FDA dataset includes analyses of data from all
patients who attended at least one evaluation visit, even if
they subsequently dropped out of the trial prematurely.
Results are reported from all well-controlled efﬁcacy trials of
Figure 1. QUOROM Flow Chart
doi:10.1371/journal.pmed.0050045.g001
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FDA medical and statistical reviewers had access to the raw
data and evaluated the trials independently. The ﬁndings of
the primary medical and statistical reviewers were veriﬁed by
at least one other reviewer, and the analysis was also assessed
by an independent advisory panel. Following FDA standards,
all trials were randomized, double-blind, placebo-controlled
trials. None used cross-over designs. Patients had been
diagnosed as suffering from unipolar major depressive
disorder using Diagnostic and Statistical Manual of Mental
Disorders (DSM) criteria.
Given the above review process, we deemed it appropriate
to include all studies deemed adequate and well controlled by
FDA reviewers, especially as these are the data upon which
the decision to approve these medications was based. Other
validity criteria might yield different conclusions. In this
review, some of the characteristics that may relate to the
quality of trials were coded and assessed as possible
moderator variables (e.g., interval of trial). The studies have
similar methodological characteristics and were well con-
trolled; therefore the methodological characteristics did not
affect the ﬁnal results.
Study Characteristics
In order to generalize the ﬁndings of the clinical trial to a
larger patient population, FDA reviewers sought a comple-
tion rate of 70% or better for these typically 6-wk trials. Only
four of the trials reported reaching this objective, and
completion rates were not reported for two trials. Attrition
rates were comparable between drug and placebo groups. Of
those trials for which these rates were reported, 60% of the
placebo patients and 63% of the study drug patients
completed a 4-, 5-, 6-, or 8-wk trial. Thirty-three trials were
of 6-wk duration, six trials were 4 wk, two were 5 wk, and six
were 8 wk. Patients were evaluated on a weekly basis. For this
meta-analysis, the data were taken from the last visit prior to
trial termination.
Thirty-nine trials focused on outpatients: three included
both inpatients and outpatients, three were conducted
among the elderly (including one of the trials with both
inpatients and outpatients), and two were among patients
hospitalized for severe depression. No trial was reported for
the treatment of children or adolescents.
Replacement of patients who investigators determined
were not improving after 2 wk was allowed in three ﬂuoxetine
trials and in the three sertraline trials for which data were
reported. The trials also included a 1- to 2-wk washout period
during which patients were given placebo, prior to random
assignment. Those whose scores improved 20% or more were
excluded from the study prior to random assignment. The use
of other psychoactive medication was reported in 25 trials. In
most trials, a chloral hydrate sedative was permitted in doses
ranging from 500 mg to 2,000 mg per day. Other psychoactive
medication was usually prohibited but still reported as having
been taken in several trials.
Meta-Analytic Data Synthesis
We conducted two types of data analysis, one in which each
group’s change was represented as a standardized mean
difference (d), which divides change by the standard deviation
of the change score (SDc) [10], and another using each study’s
drug and placebo groups’ arithmetic mean (weighted for the
inverse of the variance) as the meta-analytic ‘‘effect size’’ [11].
The ﬁrst analysis permitted a determination of the absolute
magnitude of change in both the placebo and treatment
groups. Results permitted a determination of overall trends,
analyses of baseline scores in relation to change, and for both
types of models, tests of model speciﬁcation, which assess the
extent to which only sampling error remains unexplained.
The results in raw metric are presented comparing both
groups, but because of the variation of the SDcs, the
standardized mean difference was used in moderator analyses
in order to attain better-ﬁtting models [12]. These results are
compared to the criterion for clinical signiﬁcance used by
NICE, which is a three-point difference in Hamilton Rating
Scale of Depression (HRSD) scores or a standardized mean
difference (d) of 0.50 [1].
As known SDcs were related to mean baseline HRSD scores,
these scores were used to impute missing SDc values, taking
into account both the baseline and its quadratic form and any
potential interaction of these terms with group (but in fact,
there was no evidence that SDcs depended on treatment
group). One trial reported SDcs for its drug and placebo
groups that were less than 25% the size of the other trials;
because preliminary analyses also revealed that this trial was
an outlier, these two standard deviations were treated as
missing and imputed. In total, SDcs were known for 28 groups,
could be calculated from other inferential statistics in nine
comparisons (18 groups), and were imputed in 12 compar-
isons (24 groups) (47.38%) [13,14].
Overall analyses evaluated both random- and ﬁxed-effects
models to assess effect size magnitude; because the same
trends appeared for both, for simplicity we present only
the ﬁxed-effects results. We also assumed ﬁxed-effects
assumptions in order to analyze moderators for both groups.
Both Q [15] and I
2 [16] indices were used to assess
inconsistencies from the models, not only to infer the
presence or absence of homogeneity, but also (in the case of
I
2) to assess the degree of inconsistencies among trials [17].
We assumed ﬁxed-effects models in analyzing moderators
using meta-regression procedures [11]. Analyses examining
linear and quadratic functions for baseline levels of severity
used zero-centered forms of this variable [18]. A last, mixed-
effects analysis for the amount of change used a random-
effects constant along with ﬁxed-effects moderator dimen-
sions; these models provide more conservative assessments of
moderation [19].
Because the same scale was used as the primary dependent
variable in all of these trials, we were also able to represent
results in their original metric [11]. This form of analysis
makes results more easily interpretable in terms of clinical
signiﬁcance because mean change scores are analyzed
directly, rather than being converted into effect sizes. The
analytic weights are derived from the sample size and the SDc
[11]. Finally, to show directly the amount of improvement for
each study’s drug group against its placebo group, we
calculated the difference between the change for the drug
group minus the change for the placebo group, leaving the
difference in raw units and deriving its analytic weight from
its standard error [11,12,20]. Analyses used these weights to
examine these controlled outcomes both overall and to
determine the extent to which drug-related change is a
function of initial severity.
PLoS Medicine | www.plosmedicine.org February 2008 | Volume 5 | Issue 2 | e45 0262
Severity and Antidepressant BenefitsResults
Trial Flow
Mean improvement scores were not available in ﬁve of the
47 trials (Figure 1). Speciﬁcally, four sertraline trials involving
486 participants and one citalopram trial involving 274
participants were reported as having failed to achieve a
statistically signiﬁcant drug effect, without reporting mean
HRSD scores. We were unable to ﬁnd data from these trials
on pharmaceutical company Web sites or through our search
of the published literature. These omissions represent 38% of
patients in sertraline trials and 23% of patients in citalopram
trials. Analyses with and without inclusion of these trials
found no differences in the patterns of results; similarly, the
revealed patterns do not interact with drug type. The purpose
of using the data obtained from the FDA was to avoid
publication bias, by including unpublished as well as
published trials. Inclusion of only those sertraline and
citalopram trials for which means were reported to the
FDA would constitute a form of reporting bias similar to
publication bias and would lead to overestimation of drug–
placebo differences for these drug types. Therefore, we
present analyses only on data for medications for which
complete clinical trials’ change was reported. The dataset
comprised 35 clinical trials (ﬁve of ﬂuoxetine, six of
venlafaxine, eight of nefazodone, and 16 of paroxetine)
involving 5,133 patients, 3,292 of whom had been randomized
to medication and 1,841 of whom had been randomized to
placebo.
Mean Change
Baseline HRSD scores, improvement, and sample sizes in
drug and placebo groups for each clinical trial are reported
in Table 1. As in the FDA ﬁles, studies are identiﬁed by
protocol numbers. The data from these trials can be obtained
from the FDA using FOIA requests and citing the medication
name and protocol number. The table also includes refer-
ences to published reports of the data abstracted from the
FDA ﬁles, when they could be found (using the search
methods described above). Studies in which data only from
selected sites of a multisite study were published are not cited
in the table. We have also excluded published reports in
which dropouts have been removed from the data. For each
of the trials, the pharmaceutical companies had submitted to
the FDA data in which attrition was handled by carrying
forward the last observation carried forward (LOCF) on the
patient, which was the basis in all cases of the FDA review.
These data and their corresponding citations appear in the
table. Even in the LOCF data, there sometimes are some
minor discrepancies between the published version and the
version submitted to the FDA. In some cases, for example, the
N is slightly larger in the published studies than in the data
reported to the FDA. Further complicating this problem is
the fact that occasionally, the company has published a trial
more than once, with slight discrepancies in the data between
publications. Data in the table are those reported to the FDA.
Conﬁrming earlier analyses [2], but with a substantially
larger number of clinical trials, weighted mean improvement
was 9.60 points on the HRSD in the drug groups and 7.80 in
the placebo groups, yielding a mean drug–placebo difference
of 1.80 on HRSD improvement scores. Although the differ-
ence between these means easily attained statistical signiﬁ-
cance (Table 2, Model 3a), it does not meet the three-point
drug–placebo criterion for clinical signiﬁcance used by NICE.
Represented as the standardized mean difference, d, mean
change for drug groups was 1.24 and that for placebo 0.92,
both of extremely large magnitude according to conventional
standards. Thus, the difference between improvement in the
drug groups and improvement in the placebo groups was
0.32, which falls below the 0.50 standardized mean difference
criterion that NICE suggested. The amounts of change for
drug and placebo groups varied widely around their
respective means, Q(34)s ¼ 51.80 and 74.59, p-values , 0.05,
and I
2s¼34.18 and 54.47. Thus, the mean change exhibited in
trials provides a poor description of results, and moderator
models are indicated.
Drug and Initial Severity Trends in Change
Moderator analyses examined whether drug type, duration
of treatment, and baseline severity (HRSD) scores related to
improvement. Although drug type and duration of treatment
were unrelated to improvement, the drug versus placebo
difference remained signiﬁcant, and amount of improvement
was a function of baseline severity (Table 2, Model 1a).
Speciﬁcally, the amount of improvement depended markedly
on the quadratic function of baseline severity, but the linear
function of baseline severity interacted with assignment to
drug versus placebo (Model 1b). Speciﬁcally, as Figure 2
shows, improvement from baseline operated as a \-shaped
curvilinear function in relation to baseline severity, with
those at the lowest and highest levels experiencing smaller
gains, whereas those in-between experienced larger gains; the
slope for placebo declined as severity increased, whereas the
slope for drug was slightly positive. The difference between
drug and placebo exceeded NICE’s 0.50 standardized mean
difference criterion at comparisons exceeding 28 in baseline
severity. Further analyses indicated that drug type did not
moderate this affect. Although venlafaxine and paroxetine
had signiﬁcantly (p , 0.001) larger weighted mean effect sizes
comparing drug to placebo conditions (ds ¼ 0.42 and 0.47,
respectively) than ﬂuoxetine (d ¼ 0.22) or nefazodone (0.21),
these differences disappeared when baseline severity was
controlled.
For all but one sample, baseline HRSD scores were in the
very severe range according to the criteria proposed by the
American Psychiatric Association (APA) [21] and adopted by
NICE [1]. The one exception derived from a ﬂuoxetine trial
that had two samples, one with HRSD scores in the very
severe range and the other with scores in the moderate range.
Because the low-HRSD condition might be considered an
outlier, the analyses were performed again without it. Results
continued to reveal that drug versus placebo assignment
interacted with initial severity to inﬂuence improvement; yet
the curvilinear function of the baseline was no longer
signiﬁcant, although group continued to interact with the
linear component (Table 2, Model 2c). As Figure 3 shows,
drug efﬁcacy did not change as a function of initial severity,
whereas placebo efﬁcacy decreased as initial severity in-
creased; values again exceeded NICE’s 0.50 standardized
mean difference criterion at comparisons greater than 28 in
baseline severity. This ﬁnal model comprising three simulta-
neous study dimensions (viz., drug vs. placebo, baseline, and
the interaction) explained 51.45% of the variation in
improvement. Although this model was in a formal sense
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random-effects constant was instead assumed, the same
pattern of results remained in this more statistically
conservative mixed-effects model. A ﬁnal model that incor-
porated even the drug types for which only some trials were
available conﬁrmed these trends.
Figure 4 displays raw mean differences between drug and
placebo as a function of initial severity, rising as a linear
function of baseline severity levels (Table 2, Models 3a and
3b) even though, almost without exception, the scores were in
the very severe range of the criteria proposed by APA [21].
Yet when these data are considered in conjunction with those
in Figure 3, it seems clear that the increased difference is due
to a decrease in improvement in placebo groups, rather than
an increase in drug groups.
A visual inspection of Figure 4 suggests that studies’ effects
are fairly evenly distributed above and below the NICE
criterion (3) but that most small studies have high baselines
and show large effects. Although sample size (N)w a s
negatively linked to the drug-versus-placebo differences (b ¼
 0.34, p ¼ 0.003), when mean baseline severity values are
controlled, this effect disappears and the baseline effect
remains signiﬁcant. The interaction of sample size with
baseline severity was marginally signiﬁcant, p ¼ 0.0586, and
the pattern indicated that baseline severity was somewhat
more predictive for smaller than for larger studies. Yet,
because simple-slopes analyses revealed that baseline scores
were signiﬁcantly predictive even for the largest studies, study
differences in sample size would appear to qualify neither the
pattern of results we have reported nor their interpretation.
Examination of publication bias often relies on inspections
of effect sizes in relation to sample size (or inverse variance)
[22]. A funnel plot of the data depicted in Figure 4 indicates
that the larger studies in the FDA datasets tended to show
smaller drug effects than smaller studies. Although such a
pattern might be construed as indicating a publication or
other reporting bias, our use of complete datasets precludes
this possibility, unless some small trials were not reported
despite the FDA Guidelines [6]. A more plausible explanation
is that trials with higher baseline scores tended to be small. In
Table 1. Baseline HRSD Scores, Sample Sizes, and Raw and Standardized Improvement with Confidence Intervals, as Reported to the
FDA for Drug and Placebo Groups
Drug (Manufacturer) Drug Placebo
Protocol Number
a Baseline Change d [95% CI] dN Baseline Change d [95% CI] dN
Fluoxetine (Eli Lilly and Company) 19 [27] 28.6 12.5 1.44 [0.79, 2.09] 22 28.2 5.5 0.63 [0.17, 1.10] 24
25 26.2 7.2 0.83 [0.24, 1.41] 18 25.8 8.8 1.03 [0.50, 1.56] 24
27 [28] 27.5 11 1.15 [0.96, 1.34] 181 28.2 8.4 0.88 [0.69, 1.06] 163
62 (mild) [29] 17 5.89 1.02 [0.88, 1.16] 299 17.4 5.82 1.05 [0.71, 1.38] 56
62 (moderate) 24.3 8.82 1.13 [0.98, 1.27] 297 24.3 5.69 0.72 [0.39, 1.05] 48
Venlafaxine (Wyeth Pharmaceuticals) 203 [30] 25.6 11.2 1.37 [1.19, 1.55] 231 25.3 6.7 0.82 [0.58, 1.06] 92
301 [31,32] 25.4 13.9 1.77 [1.36, 2.17] 64 24.6 9.45 1.20 [0.91, 1.50] 78
302 [33] 25 11.9 1.16 [0.84, 1.49] 65 24.4 8.88 0.87 [0.60, 1.14] 75
303 23.6 10.1 1.27 [0.94, 1.59] 69 24.6 9.89 1.24 [0.94, 1.54] 79
313 [34,35] 25.7 11 1.34 [1.16, 1.52] 227 25.4 9.49 1.15 [0.85, 1.45] 75
206 [31,36] 28.2 14.2 1.45 [1.02, 1.89] 46 28.6 4.8 0.43 [0.12, 0.74] 47
Nefazodone (Bristol-Myers Squibb) 03A0A-003 [37] 25.4 9.57 1.15 [0.90, 1.41] 101 25.9 8 0.92 [0.59, 1.26] 52
03A0A-004A 23.4 8.9 1.17 [0.97, 1.38] 153 23.5 8.9 1.17 [0.88, 1.47] 77
03A0A-004B [38] 25.3 11.4 1.41 [1.18, 1.63] 156 25 9.5 1.17 [0.87, 1.47] 75
030A2–0004 / 0005 23.4 10 1.31 [0.99, 1.63] 74 24 9.84 1.27 [0.94, 1.59] 70
030A2–0007 [39] 25.7 12.3 1.42 [1.20, 1.63] 175 26.4 9.8 1.11 [0.74, 1.49] 47
CN104–002 23.3 10.8 1.36 [0.99, 1.73] 57 23.1 8.2 1.03 [0.70, 1.36] 57
CN104–005 [40] 24.5 12 1.51 [1.20, 1.83] 86 23.3 8 1.01 [0.75, 1.27] 90
CN104–006 23.8 10 1.34 [1.03, 1.65] 80 23.5 8.9 1.20 [0.90, 1.49] 78
Paroxetine (GlaxoSmithKline) 01–001 28 13.5 1.67 [0.99, 2.34] 24 27.4 10.5 1.30 [0.71, 1.88] 24
02–001 [41,42] 26.6 12.3 1.28 [0.89, 1.66] 51 25.9 6.8 0.70 [0.39, 1.01] 53
02–002 [43,44] 25 10.9 1.23 [0.78, 1.69] 36 24.9 5.8 0.66 [0.27, 1.04] 34
02–003 [45] 28.6 9.7 0.93 [0.50, 1.35] 33 28.9 7.2 0.69 [0.29, 1.08] 33
02–004 [46] 28.9 12.7 1.87 [1.29, 2.44] 36 27.3 7.6 1.12 [0.70, 1.54] 38
03–001 [47,48] 24.9 10.8 1.60 [1.11, 2.09] 40 24.8 4.7 0.69 [0.33, 1.06] 38
03–002 [49,50] 24.9 8 1.14 [0.72, 1.55] 40 25.6 6.2 0.88 [0.50, 1.26] 40
03–003 25.7 9.9 1.18 [0.76, 1.59] 41 27 10 1.19 [0.78, 1.60] 42
03–004 [51] 27.6 10.4 1.33 [0.86, 1.79] 37 27 6.7 0.86 [0.46, 1.25] 37
03–005 [52] 26.1 10 0.99 [0.60, 1.39] 40 26.8 4.1 0.41 [0.08, 0.73] 42
03–006 [53] 29.7 9.1 1.11 [0.69, 1.52] 39 28.7 3 0.37 [0.02, 0.71] 37
PAR 09 [54] 25.2 9.1 1.28 [1.15, 1.41] 403 24.5 8.2 1.14 [0.77, 1.50] 51
UK 06 [55] 23.7 6 0.97 [0.38, 1.57] 19 24.2 6.2 0.83 [0.31, 1.35] 22
UK 12 22.8 9.1 1.23 [0.57, 1.88] 19 22.3 6.7 0.86 [0.00, 1.73] 10
UK 09 26.8 8.8 0.80 [0.26, 1.35] 20 25.5 4.5 0.49 [0.01, 0.97] 21
PAR 07 30.5 13.1 1.20 [0.38, 2.03] 13 28.3 10.9 0.99 [0.19, 1.79] 12
aWhere available, published versions of the FDA trials are cited next to the protocol number. Citations are restricted to publications in which LOCF results were published for all sites
participating in the trial. In some instances, there are minor differences in sample sizes and means between the data as submitted to the FDA and as published, and also between the data
as reported for the same trial in different publications.
doi:10.1371/journal.pmed.0050045.t001
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one population effect size that can be tracked by a
comparison between drug and placebo groups, whereas the
current investigation shows that these effects vary widely and
that the magnitude of the difference depends on initial
severity values. Consequently, funnel-plot inspection is much
less appropriate in the present context. Unfortunately, there
are no other tools yet available to detect publication or other
reporting biases in the face of effect modiﬁers.
Discussion
Using complete datasets (including unpublished data) and a
substantially larger dataset of this type than has been
previously reported, we ﬁnd that the overall effect of new-
generation antidepressant medications is below recommen-
ded criteria for clinical signiﬁcance. We also ﬁnd that efﬁcacy
reaches clinical signiﬁcance only in trials involving the most
extremely depressed patients, and that this pattern is due to a
Table 2. Models of Improvement in Depression Scores Based on Group Assignment (Drug versus Placebo) and Initial Depression
Severity (as Gauged by HRSD)
Model Factor(s) Coefficients p-Value
Unstandardized [95% CI] Standardized
Model 1a (all 35 studies) Drug vs. placebo 0.32 [0.25, 0.40] 0.61 ,0.001
Baseline severity, linear component  0.034 [ 0.055,  0.012]  0.35 0.002
Baseline severity, quadratic component  0.0068 [ 0.0099,  0.0038]  0.50 ,0.001
Model 1b (same 35 studies,
Model 1a variables þ interaction)
Drug vs. placebo 3 baseline (linear) 0.056 [0.023, 0.089] 0.50 ,0.001
Model 2a (34 studies with mean
baseline HRSD scores over 18)
Drug vs. placebo 0.33 [0.26, 0.41] 0.62 ,0.001
Baseline severity, linear component  0.031 [ 0.058,  0.0048]  0.18 0.02
Baseline severity, quadratic component  0.0079 [ 0.021, 0.0051]  0.10 0.23
Model 2b (same 34 studies) Drug vs. placebo 0.32 [0.25, 0.40] 0.61 ,0.001
Baseline severity, linear component  0.0033 [ 0.010, 0.017] 0.03 0.02
Model 2c (same 34 studies,
Model 2b variables þ interaction)
Drug vs. placebo 3 baseline (linear) 0.073 [0.025, 0.12] 0.29 0.003
Model 3a (all 35 studies) Baseline severity, linear component 0.40 [0.23, 0.57] 0.52 ,0.001
Model 3b (34 studies with mean
baseline HRSD scores over 18)
Baseline severity, linear component 0.61 [0.29, 0.93] 0.46 0.002
Models 1a through 2c concern analyses of the standardized mean effect size, d, comparing amount of change against baseline, calculated separately for drug and placebo groups; Models
3a and 3b concern each study’s comparison of the raw change between drug and placebo groups. These models rest on fixed-effects assumptions, but the patterns remain intact when
random-effects assumptions are incorporated.
doi:10.1371/journal.pmed.0050045.t002
Figure 2. Mean Standardized Improvement as a Function of Initial
Severity and Treatment Group
Drug improvement is portrayed as red triangles around their solid red
regression line and placebo improvement as blue circles around their
dashed blue regression line; the green shaded area indicates the point at
which comparisons of drug versus placebo reach the NICE clinical
significance criterion of d ¼ 0.50. Plotted values are sized according to
their weight in analyses.
doi:10.1371/journal.pmed.0050045.g002
Figure 3. Mean Standardized Improvement as a Function of Initial
Severity and Treatment Group, Including Only Trials Whose Samples Had
High Initial Severity
Drug improvement is portrayed as red triangles around their solid red
regression line and placebo improvement as blue circles around their
dashed blue regression line; the green shaded area indicates the point at
which comparisons of drug versus placebo reach the NICE clinical
significance criterion of d ¼ 0.50. Plotted values are sized according to
their weight in analyses.
doi:10.1371/journal.pmed.0050045.g003
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Severity and Antidepressant Benefitsdecrease in the response to placebo rather than an increase in
the response to medication.
Similar to prior reports [3,4], this analysis of U.S. FDA data
for four new-generation antidepressants suggests an associ-
ation between initial severity and the beneﬁt of antidepres-
sant medication. Unlike prior studies, we restricted our
analysis to complete datasets that included all trials con-
ducted, whether published or not. Thus, simple publication
bias cannot underlie the results. We compared drug–placebo
differences in improvement to criteria for clinical efﬁcacy,
and we used meta-regression procedures [11] to identify the
relation of severity to improvement. Although we were able
to replicate previously reported decreases in the placebo
response as a function of increasing baseline severity, we
found no linear relation between severity and response to
medication.
NICE used a three-point difference in HRSD change scores,
or a standardized mean difference of 0.50, as criteria of
clinical signiﬁcance [1]. By that criterion, the differences
between drug and placebo were not clinically signiﬁcant in
clinical trials involving either moderately or very severely
depressed patients, but did reach the criterion for trials
involving patients whose mean initial depression scores were
at the upper end of the very severe depression category
(mean HRSD baseline ’ 28; Figures 2–4). Given these data,
there seems little evidence to support the prescription of
antidepressant medication to any but the most severely
depressed patients, unless alternative treatments have failed
to provide beneﬁt.
A prior meta-analysis of published data only reported a
very small signiﬁcant difference between the antidepressant
effect of ﬂuoxetine and venlafaxine, but did not assess the
effect of baseline severity as a moderator [23]. Our analyses
failed to reveal any effect of drug type on efﬁcacy or on the
relation between severity and efﬁcacy. It is possible that
differences associated with drug type might be found with the
inclusion of clinical trials conducted after the approval
process, but analyses of head-to-head comparisons suggest
that they are not likely to be large enough to be of clinical
importance [23].
The response to placebo in these trials was exceptionally
large, duplicating more than 80% of the improvement
observed in the drug groups. In contrast, the effect of
placebo on pain is estimated to be about 50% of the response
to pain medication [24–26]. A substantial response to placebo
was seen in moderately depressed groups and in groups with
very severe levels of depression. It decreased somewhat, but
was still substantial, in groups with the most-severe levels of
depression.
Although baseline severity related to degree of improve-
ment in the drug groups, the pattern was not linear. Instead,
patients who by APA criteria were moderately depressed and
those at the very high end of the severely depressed category
(i.e., those with initial HRSD scores greater than 28) showed
less improvement than those at the lower end of the severely
depressed category. The curvilinear relation depended on
only one trial of moderately depressed patients. When that
outlier trial is excluded, there is no relation between baseline
severity and antidepressant response. However, all of the
other trials were with groups with mean initial HRSD scores
in the very severe range (i.e.,  23). What is missing from the
FDA data, however, are clinical trials with patients with initial
depression scores in the severe range (19–22), and there was
only one study with patients in the moderately depressed
range. Had groups with a wider array of baseline depression
scores been assessed, the curvilinear pattern might have been
more obvious; in which case, clinically signiﬁcant beneﬁts for
severely depressed patients might have been obtained. To
perform this task in an unbiased way, it would be necessary
for data for all approved medications to be available, even
those gathered after the medication is approved. Having all
the information available would also obviate the need to
impute missing standard deviations, a limitation of the
current investigation. Public availability of complete data
on approved mediations might be made a condition of
approval to solve these problems.
Finally, although differences in improvement increased at
higher levels of initial depression, there was a negative
relation between severity and the placebo response, whereas
there was no difference between those with relatively low and
relatively high initial depression in their response to drug.
Thus, the increased beneﬁt for extremely depressed patients
seems attributable to a decrease in responsiveness to placebo,
rather than an increase in responsiveness to medication.
Supporting Information
Text S1. QUOROM Checklist
Found at doi:10.1371/journal.pmed.0050045.sd001 (33 KB DOC).
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Severity and Antidepressant BenefitsEditors’ Summary
Background. Everyone feels miserable occasionally. But for some
people—those with depression—these sad feelings last for months or
years and interfere with daily life. Depression is a serious medical illness
caused by imbalances in the brain chemicals that regulate mood. It
affects one in six people at some time during their life, making them feel
hopeless, worthless, unmotivated, even suicidal. Doctors measure the
severity of depression using the ‘‘Hamilton Rating Scale of Depression’’
(HRSD), a 17–21 item questionnaire. The answers to each question are
given a score and a total score for the questionnaire of more than 18
indicates severe depression. Mild depression is often treated with
psychotherapy or talk therapy (for example, cognitive–behavioral
therapy helps people to change negative ways of thinking and
behaving). For more severe depression, current treatment is usually a
combination of psychotherapy and an antidepressant drug, which is
hypothesized to normalize the brain chemicals that affect mood.
Antidepressants include ‘‘tricyclics,’’ ‘‘monoamine oxidases,’’ and ‘‘se-
lective serotonin reuptake inhibitors’’ (SSRIs). SSRIs are the newest
antidepressants and include fluoxetine, venlafaxine, nefazodone, and
paroxetine.
Why Was This Study Done? Although the US Food and Drug
Administration (FDA), the UK National Institute for Health and Clinical
Excellence (NICE), and other licensing authorities have approved SSRIs
for the treatment of depression, some doubts remain about their clinical
efficacy. Before an antidepressant is approved for use in patients, it must
undergo clinical trials that compare its ability to improve the HRSD
scores of patients with that of a placebo, a dummy tablet that contains
no drug. Each individual trial provides some information about the new
drug’s effectiveness but additional information can be gained by
combining the results of all the trials in a ‘‘meta-analysis,’’ a statistical
method for combining the results of many studies. A previously
published meta-analysis of the published and unpublished trials on
SSRIs submitted to the FDA during licensing has indicated that these
drugs have only a marginal clinical benefit. On average, the SSRIs
improved the HRSD score of patients by 1.8 points more than the
placebo, whereas NICE has defined a significant clinical benefit for
antidepressants as a drug–placebo difference in the improvement of the
HRSD score of 3 points. However, average improvement scores may
obscure beneficial effects between different groups of patient, so in the
meta-analysis in this paper, the researchers investigated whether the
baseline severity of depression affects antidepressant efficacy.
What Did the Researchers Do and Find? The researchers obtained data
on all the clinical trials submitted to the FDA for the licensing of
fluoxetine, venlafaxine, nefazodone, and paroxetine. They then used
meta-analytic techniques to investigate whether the initial severity of
depression affected the HRSD improvement scores for the drug and
placebo groups in these trials. They confirmed first that the overall effect
of these new generation of antidepressants was below the recom-
mended criteria for clinical significance. Then they showed that there
was virtually no difference in the improvement scores for drug and
placebo in patients with moderate depression and only a small and
clinically insignificant difference among patients with very severe
depression. The difference in improvement between the antidepressant
and placebo reached clinical significance, however, in patients with initial
HRSD scores of more than 28—that is, in the most severely depressed
patients. Additional analyses indicated that the apparent clinical
effectiveness of the antidepressants among these most severely
depressed patients reflected a decreased responsiveness to placebo
rather than an increased responsiveness to antidepressants.
What Do These Findings Mean? These findings suggest that, compared
with placebo, the new-generation antidepressants do not produce
clinically significant improvements in depression in patients who initially
have moderate or even very severe depression, but show significant
effects only in the most severely depressed patients. The findings also
show that the effect for these patients seems to be due to decreased
responsiveness to placebo, rather than increased responsiveness to
medication. Given these results, the researchers conclude that there is
little reason to prescribe new-generation antidepressant medications to
any but the most severely depressed patients unless alternative
treatments have been ineffective. In addition, the finding that extremely
depressed patients are less responsive to placebo than less severely
depressed patients but have similar responses to antidepressants is a
potentially important insight into how patients with depression respond
to antidepressants and placebos that should be investigated further.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050045.
  The MedlinePlus encyclopedia contains a page on depression (in
English and Spanish)
  Detailed information for patients and caregivers is available on all
aspects of depression (including symptoms and treatment) from the
US National Institute of Medical Health and from the UK National
Health Service Direct Health Encyclopedia
  MedlinePlus provides a list of links to further information on
depression
  Clinical Guidance for professionals, patients, caregivers and the public
is provided by the UK National Institute for Health and Clinical
Excellence
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